907 related articles for article (PubMed ID: 27468211)
41. Hepatitis C Virus-Associated Non-Hodgkin Lymphomas: Biology, Epidemiology, and Treatment.
Pozzato G; Mazzaro C; Gattei V
Clin Liver Dis; 2017 Aug; 21(3):499-515. PubMed ID: 28689589
[TBL] [Abstract][Full Text] [Related]
42. Hepatitis C virus infection in subsets of neoplastic lymphoproliferations not associated with cryoglobulinemia.
Luppi M; Grazia Ferrari M; Bonaccorsi G; Longo G; Narni F; Barozzi P; Marasca R; Mussini C; Torelli G
Leukemia; 1996 Feb; 10(2):351-5. PubMed ID: 8637247
[TBL] [Abstract][Full Text] [Related]
43. Hepatitis C virus infection and antiviral treatment in marginal zone lymphomas.
Arcaini L; Bruno R
Curr Clin Pharmacol; 2010 May; 5(2):74-81. PubMed ID: 20156155
[TBL] [Abstract][Full Text] [Related]
44. Hepatitis C infection and lymphoproliferative disease: accidental comorbidities?
Khoury T; Chen S; Adar T; Jacob EO; Mizrahi M
World J Gastroenterol; 2014 Nov; 20(43):16197-202. PubMed ID: 25473174
[TBL] [Abstract][Full Text] [Related]
45. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis.
Lamprecht P; Lerin-Lozano C; Merz H; Dennin RH; Gause A; Voswinkel J; Peters SO; Gutzeit O; Arlt AC; Solbach W; Gross WL
Ann Rheum Dis; 2003 Dec; 62(12):1230-3. PubMed ID: 14644867
[TBL] [Abstract][Full Text] [Related]
46. HCV-associated mixed cryoglobulinemia and b-cell non-Hodgkin's lymphoma - pathogenetically related problems.
Milovanova SY; Lysenko Kozlovskaya LV; Milovanova LY; Mrykhin NN; Russkih AV; Muchin NA
Ter Arkh; 2018 Jun; 90(6):112-120. PubMed ID: 30701914
[TBL] [Abstract][Full Text] [Related]
47. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
[TBL] [Abstract][Full Text] [Related]
48. Hepatitis C virus and lymphoma.
Paydas S
Crit Rev Oncol Hematol; 2015 Mar; 93(3):246-56. PubMed ID: 25457774
[TBL] [Abstract][Full Text] [Related]
49. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
50. Detection of occult low-grade b-cell non-Hodgkin's lymphoma in patients with chronic hepatitis C infection and mixed cryoglobulinemia.
Rasul I; Shepherd FA; Kamel-Reid S; Krajden M; Pantalony D; Heathcote EJ
Hepatology; 1999 Feb; 29(2):543-7. PubMed ID: 9918933
[TBL] [Abstract][Full Text] [Related]
51. NCCN preliminary non-Hodgkin's lymphoma practice guidelines.
Oncology (Williston Park); 1997 Nov; 11(11A):281-46. PubMed ID: 9430195
[No Abstract] [Full Text] [Related]
52. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas.
Feugier P
Future Oncol; 2015; 11(9):1327-42. PubMed ID: 25952779
[TBL] [Abstract][Full Text] [Related]
53. Heterogeneity and coexistence of oncogenic mechanisms involved in HCV-associated B-cell lymphomas.
Carloni G; Fioretti D; Rinaldi M; Ponzetto A
Crit Rev Oncol Hematol; 2019 Jun; 138():156-171. PubMed ID: 31092372
[TBL] [Abstract][Full Text] [Related]
54. Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era.
Perrone S; D'Elia GM; Annechini G; Ferretti A; Tosti ME; Foà R; Pulsoni A
Leuk Res; 2016 May; 44():53-60. PubMed ID: 27030961
[TBL] [Abstract][Full Text] [Related]
55. [Autoimmune and lymphoproliferative HCV-correlated manifestations: example of mixed cryoglobulinaemia (review)].
Ghinoi A; Mascia MT; Puccini R; Ferri C
G Ital Nefrol; 2004; 21(3):225-37. PubMed ID: 15285001
[TBL] [Abstract][Full Text] [Related]
56. Hepatitis C virus-Epstein-Barr virus interaction in patients with AIDS.
Challine D; Buisson M; Cadilhac M; Germanidis G; Joab I; Eliaszewicz M; Caumes E; Flahault A; Fillet AM; Pawlotsky JM; Seigneurin JM
J Med Virol; 2002 Aug; 67(4):510-5. PubMed ID: 12115996
[TBL] [Abstract][Full Text] [Related]
57. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
58. Viral and non-viral risk factors for non-Hodgkin's lymphoma in Egypt: heterogeneity by histological and immunological subtypes.
Goldman L; Ezzat S; Mokhtar N; Abdel-Hamid A; Fowler N; Gouda I; Eissa SA; Abdel-Hamid M; Loffredo CA
Cancer Causes Control; 2009 Aug; 20(6):981-7. PubMed ID: 19263231
[TBL] [Abstract][Full Text] [Related]
59. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience.
Vallisa D; Bernuzzi P; Arcaini L; Sacchi S; Callea V; Marasca R; Lazzaro A; Trabacchi E; Anselmi E; Arcari AL; Moroni C; Bertè R; Lazzarino M; Cavanna L
J Clin Oncol; 2005 Jan; 23(3):468-73. PubMed ID: 15659492
[TBL] [Abstract][Full Text] [Related]
60. HCV infection and non-Hodgkin lymphomas: an evolving story.
Defrancesco I; Zerbi C; Rattotti S; Merli M; Bruno R; Paulli M; Arcaini L
Clin Exp Med; 2020 Aug; 20(3):321-328. PubMed ID: 32052244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
